Publication: Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
No Thumbnail Available
Identifiers
Date
2021-11-30
Authors
Powles, T
Bellmunt, J
Comperat, E
De Santis, M
Huddart, R
Loriot, Y
Necchi, A
Valderrama, B P
Ravaud, A
Shariat, S F
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
Metrics
Export
Abstract
Urothelial carcinoma (UC), also described as bladder cancer, is the 10th most common cancer type worldwide, with an estimated 549 000 new cases and 200 000 deaths in 2018. The highest incidence rates in Europe are observed in Southern Europe, e.g. Greece (5800 new cases and 1537 deaths in 2018), Spain and Italy, and Western Europe, e.g. Belgium and the Netherlands.¹ The most important risk factor for developing bladder cancer is tobacco smoking, which accounts for ~50% of cases,² followed by occupational exposure to aromatic amines and ionising radiation.
Description
MeSH Terms
Carcinoma, Transitional Cell
Follow-Up Studies
Humans
Immunoconjugates
Urinary Bladder Neoplasms
Carcinoma, Transitional Cell
Belgium
Spain
Greece
Incidence
Follow-Up Studies
Humans
Immunoconjugates
Urinary Bladder Neoplasms
Carcinoma, Transitional Cell
Belgium
Spain
Greece
Incidence
DeCS Terms
Neoplasias de la vejiga urinaria
Neoplasias
Exposición profesional
Fumar tabaco
Tabaquismo
Neoplasias
Exposición profesional
Fumar tabaco
Tabaquismo
CIE Terms
Keywords
Antibody drug conjugates, Bladder cancer, Fibroblast growth factor receptor inhibitors, Immune checkpoint inhibitors, Platinum-based chemotherapy, Urothelial carcinoma